Table 2.
Population Characteristics of the 5 Blood Pressure Treatment Goal Trials Included in the Primary Meta-analysis*
| Characteristic | AASK (19) |
ACCORD BP (20) |
SPRINT (18) |
SPS3 (21) |
UKPDS (9) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Participants, n | Value | Participants, n | Value | Participants, n | Value | Participants, n | Value | Participants, n | Value | |
| Mean age (SD), y | 1090 | 54.6 (10.7) | 4196 | 62.6 (6.6) | 9221 | 67.9 (9.4) | 2887 | 62.8 (10.7) | 1072 | 56.8 (8.0) |
| Age >75y, % | 1090 | 0.0 | 4196 | 4.8 | 9221 | 24.9 | 2887 | 13.8 | 1072 | 0.0 |
| Women, % | 1090 | 38.9 | 4196 | 46.4 | 9221 | 35.5 | 2887 | 36.6 | 1072 | 45.3 |
| Black, % | 1090 | 100.0 | 4196 | 22.3 | 9221 | 31.3 | 2887 | 16.0 | 1072 | 7.6 |
| Prerandomization seated SBP (SD), mm Hg | 1087 | 143.8 (22.3) | 4195 | 139.1 (15.7) | 9219 | 139.7 (15.6) | 2886 | 143.1 (18.8) | 1044 | 158.1 (21.9) |
| Prerandomization seated DBP (SD), mm Hg | 1088 | 88.7 (13.5) | 4195 | 75.9 (10.3) | 9220 | 78.1 (11.9) | 2887 | 78.4 (10.6) | 1047 | 92.8 (11.2) |
| Prerandomization standing SBP (SD), mm Hg | 1087 | 143.2 (23.4) | 1218 | 139.3 (16.8) | 9204 | 140.3 (17.9) | 2294 | 144.3 (22.4) | 1047 | 155.0 (22.0) |
| Prerandomization standing DBP (SD), mm Hg | 1086 | 91.5 (14.5) | 1218 | 79.1 (11.2) | 9206 | 81.8 (12.9) | 2298 | 81.1 (12.9) | 1047 | 93.7 (10.9) |
| eGFR (SD), mL/min per 1.73 m2† | 1088 | 42.4 (13.8) | 4181 | 84.6 (17.6) | 9184 | 72.4 (20.0) | 2520 | 80.7 (18.9) | 0 | Not released |
| Stage 3 CKD (SD), %‡ | 1088 | 89.5 | 4181 | 10.1 | 9184 | 27.1 | 2520 | 15.2 | 1045 | 25.3 |
| Body mass index (SD), kg/m2 | 1090 | 30.6 (6.6) | 4196 | 32.1 (5.4) | 9158 | 29.9 (5.8) | 2879 | 28.9 (5.6) | 1042 | 29.6 (5.5) |
| Obese, % | 1090 | 46.7 | 4196 | 61.3 | 9158 | 43.0 | 2879 | 35.0 | 1042 | 39.6 |
| Diabetes, % | 1090 | 6.7 | 4196 | 100.0 | 9220 | 1.6 | 2887 | 33.2 | 1072 | 100.0 |
| Prior stroke, % | NR | NR | 9218 | 0.5 | 2887 | 100.0 | 1072 | 0.3 | ||
| History of CVD, % | NR | 4196 | 32.9 | 9221 | 20.0 | 2887 | 10.6 | 1072 | 0.4 | |
| Standing SBP <110 mm Hg before randomization, % | 1087 | 5.8 | 1218 | 3.6 | 9204 | 3.2 | 2294 | 4.1 | 1047 | 0.6 |
| Pre-randomization OH, % | 1081 | 9.1 | 1218 | 7.5 | 9203 | 7.2 | 2293 | 10.2 | 1044 | 16.6 |
AASK = African American Study of Kidney Disease and Hypertension; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes: Blood Pressure; CKD = chronic kidney disease; CVD = cardiovascular disease; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; SPRINT = Systolic Blood Pressure Intervention Trial; SPS3 = Secondary Prevention of Small Subcortical Strokes; UKPDS = U.K. Prospective Diabetes Study; NR = not reported; OH = orthostatic hypotension; SBP = systolic blood pressure.
This sample was restricted to participants with a follow-up visit. The number cited in the table is not always equal to the number of participants in the original trial who underwent randomization.
Based on the CKD-EPI equation.
Defined as eGFR <60 mL/min per 1.73 m2.